The short version of lyophilized powder fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-04-26. Anything still debated is marked as such rather than presented as settled.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
The UK government announces it will overhaul what it describes as the "feudal" leasehold system in England and Wales by the end of the current parliament. A security incident at Buchanan bus station in the centre of Glasgow leads to the evacuation of the area and anti-terror police being called out; around three men are arrested in connection with the incident. 22 November Ofgem announces the price of an average energy bill will rise by £21 a year from January 2025, with the typical household paying £1,738 per year; prices are now 50% higher than pre-COVID levels. Data from the Office for National Statistics shows a 0.7% fall in retail sales during October, with people holding back on spending ahead of the budget. Downing Street indicates that Israeli Prime Minister Benjamin Netanyahu would face arrest if he travelled to the UK following the issuing of an international arrest warrant for war crimes by the International Criminal Court. The Investigatory Powers Tribunal rules that 300 people affected by the Manchester Arena bombing cannot continue with a case against MI5 in which they alleged their human rights were breached because the security agency failed to take "appropriate measures" to prevent the attack. The UK government announces plans for new "respect orders" in England and Wales, giving police and local authorities the power to ban those who persistently practice antisocial behaviour from drinking in public places or from entering town centres, with prison sentences of up to two years for those who consistently break the orders.
== Further reading == Valera, Maria José; Torija, Maria Jesús; Mas, Albert; Mateo, Estibaliz (2013). "Acetobacter malorum and Acetobacter cerevisiae identification and quantification by Real-Time PCR with TaqMan-MGB probes". Food Microbiology. 36 (1): 30–39. doi:10.1016/j.fm.2013.03.008. ISSN 0740-0020. PMID 23764217. Sagarzazu, Noelia Isabel, et al. "Optimization of denaturing high performance liquid chromatography technique for rapid detection and identification of acetic acid bacteria of interest in vinegar production." Acetic Acid Bacteria 2.1s (2013): e5. Ogawa S, Tachimoto H, Kaga T (January 2010). "Elevation of ceramide in Acetobacter malorum S24 by low pH stress and high temperature stress". Journal of Bioscience and Bioengineering. 109 (1): 32–6. doi:10.1016/j.jbiosc.2009.07.007. PMID 20129078.
19 October – The SNP appoints Carol Beattie, a former chief executive of Stirling Council, as interim chief executive following the resignation of Murray Foote. 20 October – The UK government announces plans to appoint a minister to oversee the building of HS2, as well as confirming it will not reinstate the route's Birmingham to Manchester leg. The Sunday Times reports that Rushanara Ali has given up responsibility for managing building safety after survivors of the Grenfell tower fire called for her to stand down following an article that highlighted her attendance at the Franco-British Colloque, a conference that brings together senior politicians, civil servants and business leaders. 21 October – A Freedom of Information request reveals that Suella Braverman sent government documents to her private email account 127 times while she was Attorney General, potentially breaching the ministerial code. 22 October – The Welsh Government pays a £19m tax bill for the environment agency, Natural Resources Wales, following a HM Revenue and Customs investigation into how the agency hired specialist contractors. The UK signs what it has described as a "landmark defence agreement" with Germany. 23 October – Charles III and Camilla arrive in Samoa for a state visit, where the King will preside over the 2024 Commonwealth Heads of Government Meeting. The Senedd votes 26–19 to defeat a motion calling for a new law to allow assisted dying in England and Wales.
Sources: en.wikipedia.org
Protein phosphorylation, a post-translational modification, helps to regulate protein function and involves the phosphorylation of amino acids with hydroxyl groups in their side chains (among eukaryotes). Serine, threonine, and tyrosine amino acids are common targets of phosphorylation. Phosphorylation of Hsp70 has become a point of greater exploration in scientific literature relatively recently. A 2020 publication suggests that phosphorylation of a serine residue between the NBD and substrate binding domain in yeast Hsp70s leads to a dramatic reduction of the normal Hsp70 heat shock response. This deactivation via phosphorylation of a protein is a common motif in protein regulation, and demonstrates how relatively small changes to protein structure can have biologically significant effects on protein function.
Colombia topped their first-round group at the 1991 Copa América in Chile, beating Brazil 2–0 along the way, but lost all three matches in the four-team final round to finish fourth. Maturana returned in 1993 to oversee qualification for the 1994 FIFA World Cup. With Valderrama as captain, Colombia reached the semi-finals of the 1993 Copa América, eliminating Uruguay on penalties in the quarter-finals before losing 6–5 on penalties to Argentina after a goalless semi-final in Guayaquil. Adolfo Valencia scored the only goal in a 1–0 win over the hosts Ecuador in the third-place match in Portoviejo. Colombia went through the 1994 qualifying group unbeaten, winning four and drawing two of six matches and conceding twice. The campaign closed on 5 September 1993 at the Estadio Monumental in Buenos Aires, where a 5–0 victory over Argentina — two goals each for Rincón and Faustino Asprilla, and a fifth from Adolfo Valencia — sealed qualification and consigned the 1990 finalists to a play-off. The result made Colombia among the most widely tipped sides for the finals; Pelé named them his favourites for the title.
Oral: Capsules: Prometrium (100 mg, 200 mg, 300 mg) Vaginal: Tablets: Endometrin (100 mg); Gels: Crinone (4%, 8%) Intramuscular injection: Oil: Progesterone (50 mg/mL) A 25 mg/mL concentration of progesterone oil for intramuscular injection and a 38 mg/device progesterone intrauterine device (Progestasert) have been discontinued. An oral combination formulation of micronized progesterone and estradiol in oil-filled capsules (brand name Bijuva) is marketed in the United States for the treatment of menopausal symptoms and endometrial hyperplasia. Progesterone is also available in unregulated custom preparations from compounding pharmacies in the United States. In addition, transdermal progesterone is available over-the-counter in the United States, although the clinical efficacy of transdermal progesterone is controversial.
A Squadron: 1 (Boat) Troop – 2 (Air) Troop – 3 (Mobility) Troop – 4 (Mountain) Troop B Squadron: 6 (Boat) Troop – 7 (Air) Troop – 8 (Mobility) Troop – 9 (Mountain) Troop D Squadron: 16 (Air) Troop – 17 (Boat) Troop – 18 (Mobility) Troop – 19 (Mountain) Troop G Squadron: 21 (Mobility) Troop – 22 (Mountain) Troop – 23 (Boat) Troop – 24 (Air) Troop
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.